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Background: Our recent evidence showed that Toll like receptor 9 (TLR9) signaling could enhance the growth and
metastatic potential of human lung cancer cells through repressing microRNA-7 (miR-7) expression. Human antigen
R (HuR) has been involved in stabilizing multiple mRNAs in cellular biology. However, whether HuR also contributed
to the altered expression of miR-7 in TLR9 signaling stimulated human lung cancer cells remains to be elucidated.
Methods: The expression of HuR in human lung cancer 95D cells treated with TLR9 agonist CpG Oligonucleotides
(ODNs) was detected by Real-time PCR and Western blot assay. To explore the possible role of HuR on miR-7
expression, eukaryotic expression vector encoding HuR was transiently transfected into 95D cells and then the
expression of miR-7 was detected by Real-time PCR assay. Moreover, RNA interference, western blot, Real-time PCR,
MTT assay, BrdU labeling, invasion assay and scratch assay were employed to examine the disrupt effect of HuR on
miR-7 expression in human lung cancer cells treated with CpG ODNs. Finally, inhibitors for PI3K, Akt or Erk
respectively, and western blot were performed to explore the possible signaling pathway related to HuR expression
in CpG ODNs treated human lung cancer cells.
Results: Our data showed that TLR9 agonist CpG ODNs could induce the expression of HuR in human lung cancer cells.
Moreover, overexpression of HuR could reduce the expression of miR-7 in lung cancer cells. Notably, down-regulation of
HuR using RNA interference restored miR-7 expression in CpG ODNs treated lung cancer cells, accompanied by
enhanced growth and metastatic potential. Finally, CpG ODNs could induce HuR expression through Akt pathway.
Conclusion: Our findings indicated that HuR could act as regulator in regulating TLR9 signaling associated biological
effect in human lung cancer cells, which might be helpful for the understanding of the potential role of HuR in tumor
biology.
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Accumulating evidence showed that Toll-like receptors
9 (TLR9), which were mainly expressed on immune cells,
were also functional expressed on lung cancer cells [1-3].
And TLR9 signaling could alter biological character of
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reproduction in any medium, provided the orindicating that activation of TLRs signaling in lung
cancer cells could contribute to the progression of lung
cancer [4-8]. Recent literatures further showed that
miRNAs, a major class of gene expression regulators,
played critical roles in regulating the biological effects
of TLR9 signaling pathway on various cells. As such,
miR-17-92 cluster might regulate the biological effect
of CpG ODNs on chronic lymphocytic leukemia (CLL)
cells [9]. One newly evidence also showed that upregulation
of miRNA-574-5p was critical for TLR9 signaling enhanced
tumor progression of human lung cancer [10]. However,his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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TLR9 signaling-associated miRNAs in lung cancer cells
remains largely unknown.
MicroRNA-7 (miR-7), a unique member of miRNAs,
played an important role in the progression of various
tumors including lung cancer [11-13]. Mechanistic evidence
showed that miR-7 could regulate the transduction of Akt
pathway, which was critical for growth and metastasis of
tumor cells [14,15]. Our most recent study also showed
that downregulation of intrinsic miR-7 was important for
TLR9 signaling enhanced growth and metastatic potential
of human lung cancer cells [16]. However, the mechanism
that downregulation of miR-7 in TLR9 signaling treated
lung cancer cells remains to be investigated. Recent evi-
dence showed that Human antigen R (HuR), a post-
transcriptional regulator of gene expression, played a key
role in stabilizing multiple mRNAs in cellular biology
[17-19]. Interestingly, one research work further showed
that HuR could regulate the expression of miR-7 in
nonneural cells in brain [20]. However, whether HuR
was also involved in the expression of miR-7 in TLR9
signaling treated lung cancer cells still remains to be
elucidated. Here, we carefully evaluated the potential role
of HuR in the expression of miR-7 on TLR9 signaling
treated human lung cancer cells.Results and discussion
TLR9 signaling enhanced the expression of HuR in human
lung cancer cells
To investigate the potential role of HuR on the expression
of miR-7, we firstly detected the expression of HuR in
CpG ODNs, TLR9 agonist, treated human lung cancer
cells. As shown in Figure 1A and B, we found that CpG
ODNs could significantly enhance the expression of HuR
mRNA and protein in human lung cancer cell line 95D
cells in a dose dependent manner (p < 0.05). Next, we
further detected the expression of miR-7 on 95D cells. As
shown in Figure 1C, the expression of miR-7 decreased
during the stimulation of CpG ODNs, accompanied by
elevated expression of HuR (p < 0.05), which was consistent
with our previous data [16].
Our previous study showed that CpG ODNs could
also reduce miR-7 expression in other lung cancer cells
such as BE1, NCI-H727 and SPCA/I [16], which also
expressed TLR9 molecule (data not shown). Then, to
confirm above phenomenon, we observed the expression
level of HuR in lung cancer cell line BE1, NCI-H727 and
SPCA/I cells. Consistently, we found that CpG ODNs
also obviously elevated the expression level of HuR in
BE1, NCI-H727 and SPCA/I respectively (Figure 1D,
p < 0.05). These data strongly suggested that TLR9
signaling could significantly enhance the expression of
HuR in lung cancer cells.Overexpression of HuR reduced the expression of miR-7
in human lung cancer cells
Next, we further investigated whether HuR could regulate
the expression of miR-7 in human lung cancer cells. We
constructed and transiently transfected the eukaryotic
expression vector encoding HuR (termed as pHuR) into
human lung cancer cells. Our data showed that expression
level of HuR in pHuR transfected group was higher than
that in control group (Figure 2A, p < 0.05). Importantly,
we found that the expression of miR-7 decreased obvi-
ously in pHuR transfected group in a time dependent
manner (Figure 2B and C, p < 0.05).
To validate these finding, we further observed the effect
of HuR overexpression on the expression of miR-7 in
other lung cancer cells. Similarly, the expression level of
miR-7 in pHuR transfected human lung cancer cells BE1,
NCI-H727 and SPCA/I also decreased respectively
(Figure 2D, p < 0.05). These data demonstrated that HuR
could regulate the expression of miR7 in human lung
cancer cells.Down-regulation of HuR elevated the expression of miR-7
in CpG ODNs treated human lung cancer cells
To determine whether up-regulation of HuR contributed
to TLR9 signaling induced repression of miR-7, we
downregulated HuR expression using RNAi and then
detected the expression of miR-7 in human lung cancer
cells. As shown in Figure 3A, HuR RNAi could significantly
reduce the expression of HuR in CpG ODNs treated 95D
cells (p < 0.05). Importantly, we found that the expression
level of miR-7 in HuR RNAi transfected group treated with
CpG ODNs was significantly higher than that in control
group (Figure 3B, p < 0.05), indicating that downregulation
of HuR could reverse the expression of miR-7 in human
lung cancer cells.Down-regulation of HuR abrogated TLR9 signaling
enhanced growth and metastatic potential of human
lung cancer cells
Our previous data showed that TLR9 signaling could en-
hance the growth and metastatic potential of human lung
cancer cells through altering miR-7 expression [7,16]. Then,
we further investigated whether up-regulation of HuR was
involved in the effect of TLR9 signaling on human lung
cancer cells. As shown in Figure 4A and B, we found that
CpG ODNs stimulation could effectively increase the
growth of in 95D cells in vitro, which was consistent with
our previous work [7]. Importantly, we found that TLR9
signaling enhanced growth of 95D cells was significantly
reduced in HuR RNAi transfected group in vitro (Figure 4A
and B, p < 0.05), indicating down-regulation of HuR could
reduce TLR9 signaling enhanced growth of human lung
cancer cells.
Figure 1 TLR9 signaling enhanced the expression of HuR in human lung cancer cells. (A) 95D cells were treated with indicated dose of
CpG ODNs. 72 hrs later, the expression level of HuR mRNA was detected by Realtime PCR assay. (B) The expression of HuR protein also was
detected by Western Blot and calculated. (C). 95D cells were treated with 10 μg/ml CpG ODNs. Then, the expression of miR-7 and HuR were
analyzed at indicated time point. (D) Human lung cancer cell line BE1, NCI-H727 and SPCA/I cells were treated with 10 μg/ml CpG-ODNs
respectively for 72 hrs. Then the expression level of HuR mRNA was detected by Realtime-PCR assay. One representative data of three
independent experiments was shown.
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of HuR could also influence the metastatic potential of
95D cells enhanced by TLR9 signaling. As shown in
Figure 4C and D, TLR9 signaling enhanced migration
and invasion capacity of 95D cells in vitro was also signifi-
cantly reduced in HuR RNAi transfected group (p < 0.05).
Combining these data suggested that up-regulation of
HuR was be involved in TLR9 signaling enhanced growth
and metastatic potential of human lung cancer cells.TLR9 signaling enhanced the expression of HuR through
Akt pathway in human lung cancer cells
Previous works showed that PI3K pathway inhibitor
could alter the expression of HuR in human hepatoma
cell line, suggesting PI3K/Akt pathway was important for
HuR expression [21]. To reach a comprehensive under-
standing, we further treated 95D cell with PI3K inhibitor
(LY294002) and specific MEK (Mitogen-activated protein
kinase) inhibitor (U0126). As shown in Figure 5A, Akt
inhibitor completely blocked TLR9 signaling induced
expression of HuR (p < 0.05). However, the expression of
HuR in U0126 treated group did not change significantly
(p > 0.05), indicating ERK1/2 did not involved in TLR9
signaling induced HuR expression in lung cancer cells.To further confirm the role of PI3K/Akt pathway in
TLR9 signaling induced HuR expression, we next treated
95D cells with Akt inhibitor. Consistently, Akt inhibitor
also could reduce the expression of HuR induced by CpG
ODNs (Figure 5A, p < 0.05). In addition, the expression
level of miR-7 also increased significantly (data not shown),
which was consistent with our previous work [16]. Comb-
ing these data suggested that PI3K/Akt pathway was critical
for TLR9 signaling induced expression of HuR in human
lung cancer cells.Discussion
Accumulating evidence showed that HuR was expressed
in various tumor cells and played an important role in
the biology of various tumor cells through post-tran-
scriptionally regulating the stabilization of multiple AU-
rich element-bearing mRNAs [17,22,23]. Such as, Kurosu
et al. reported that HuR could keep an angiogenic switch
on by stabilising mRNA of VEGF and COX-2 in tumor
endothelium [18]. Moreover, Blaxall et al. found that the
expression of HuR was important for the maintenance
and progression of tumor cells in neoplastic lung tissue
[24]. Recently, Kim et al. further reported that HuR
was highly expressed on clinical lung cancer tissues
Figure 2 Overexpression of HuR reduced the expression of miR-7 in human lung cancer cells. 5 × 104 95D cells were transiently
transfected with plasmid p-HuR (100 μg) or p-Cont (100 μg) and cultured in 24-well plate. (A) 72 hrs later, the expression of HuR was analyzed by
Western Blot and calculated. (B) The relative expression of miR-7 was determined by Realtime PCR assay. (C) 95D cells were transiently
transfected with plasmid p-HuR (100 μg) or p-Cont (100 μg). The relative expression of miR-7 was further determined by Real-time PCR assay at
indicated time point. (D) Human lung cancer cell line BE1, NCI-H727 and SPCA/I cells were also transiently transfected with 100 μg plasmid
p-HuR or p-Cont and cultured in 24-well plate respectively. 72 hrs later, the relative expression of miR-7 also was determined by Real-time PCR
assay. One representative data of three independent experiments was shown.
Figure 3 Down-regulation of HuR reversed the expression of miR-7 in CpG ODNs treated human lung cancer cells. 95D cells were
transiently transfected with HuR RNAi (10 nmol) or control RNAi (10 nmol) respectively and then treated with CpG ODNs (10 μg/ml). 72 hrs later,
the expression of HuR was determined by western blot and calculated (A). (B) The relative expression level of miR-7 was detected by Real-time
PCR assay. One representative data of three independent experiments was shown.
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Figure 4 Down-regulation of HuR reduced TLR9 signaling enhanced growth and metastatic potential of human lung cancer cells. 95D
cells transiently transfected with HuR RNAi (10 nmol) or control RNAi (10 nmol) were cultured in the presence of 10 μg/ml CpG ODNs. 72 hrs
later, the proliferation of cells also was determined by MTT assay (A) and BrdU incorporation assay (B). (C) The migration of 95D cells in each
group was performed by transwell assay. (D) The invasion ability of 95D cells in each group also was determined by invasion assay. One
representative data of three independent experiments was shown.
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[25]. Our present work extended these previous works by
demonstrating that TLR9 signaling could enhance the
expression of HuR. Importantly, we further found that
up-regulation of HuR was contributed to TLR9 signaling
enhanced growth and metastatic potential of human lung
cancer cells. These finding might support the fact that HuR
could be an important intrinsic regulator in distinct tumor
cells, which ultimately contributed to tumor biology.
Recently, miR-7 was reported played an important role
in regulating the biology of various tumor cells through
repressing the expression of different target molecules. In
previous study, we reported down-regulation of intrinsic
miR-7 was critical for TLR9 signaling enhanced progression
of human lung cancer cells through altering the expression
of PIK3R3 [16]. As a tumor suppressor, the expression
of miR-7 was commonly repressed in tumor cells. Such as,
Kong et al. reported that activated macrophage-derived
small molecule could reduce the expression of miR-7
in gastric tumor cells [26]. Reddy et al. reported that
homeodomain transcription factor (HoxD10) could regu-
late the expression of miR-7 through binding to the pro-
moter site of miR-7 in breast cancer cells [27]. Our current
work further reported that HuR could regulate the expres-
sion of miR-7 in human lung cancer cells. Consistently,Choudhury et al. found that HuR could bind to the con-
served terminal loop of pri-miR-7 and regulate the expres-
sion of miR-7 in nonneural cells in brain tissue [21]. In
addition, it should be noted that our previous data also
showed the activity of miR-7 promoter also decreased
in TLR9 signaling treated human lung cancer cells
[16]. Combining these data suggested that the underlying
mechanism regulating expression of distinct miRNAs such
as miR-7 in different cells was distinct and complex, which
related to different transcriptional and post-transcriptional
mechanisms. Therefore, the related transcriptional mech-
anism still remains to be further elucidated.
Some literatures showed that the expression of HuR was
regulated through transcriptional and post-transcriptional
mechanisms [28,29]. For example, Mansfield et al. reported
that Neuron-specific ELAV/Hu proteins suppress HuR
mRNA during neuronal differentiation by alternative
polyadenylation [30]. Dai et al. further found that HuR
could autoregulate its expression by promoting alternative
polyadenylation site usage [31]. However, the possible sig-
naling pathway involved in regulation on HuR expression
remains largely unknown. It was well documented that
PI3K/Akt pathway was a critical for tumor biology.
Our previous study also showed that PI3KAkt pathway
was critical for TLR9 signaling enhanced metastatic
Figure 5 TLR9 signaling induced the expression of HuR through Akt pathway. 95D cells were treated with 50 μM PI3K inhibitor (LY294002)
or specific MEK (Mitogen-activated protein kinase) inhibitor (U0126), 2.5 μM Akt inhibitor IV respectively, and then cultured in 24-well plate in the
presence of 10 ug/ml CpG ODNs. 72 hrs later, the expression of HuR protein was determined by western blot and calculated (A). (B) Schematic
diagram for TLR9 signaling induced expression of HuR.
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further demonstrated that TLR9 signaling could enhance
the expression of HuR through Akt pathway, which ultim-
ately reduce the expression of miR-7, suggesting that PI3K/
Akt pathway was important for the expression of HuR in
cancer cells. Similarly, one most newly work also reported
that Akt signaling could enhance the expression of HuR,which binded to Grb10 and inhibits apoptosis of renal
proximal tubule cells by amplifying Akt signaling through
a positive feedback loop [21]. In additions, we also found
that overexpression of miR-7 could significantly reduce
the expression of HuR in CpG ODNs treated human lung
cancer cells (Additional file 1: Figure S1), through inhibiting
the transduction of PI3K/Akt pathway [16]. Therefore,
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treatment of TLR9 agonist CpG ODNs on human lung
cancer cells, TLR9 signaling induced the expression of
HuR via PIK3/Akt pathway. Up-regulated HuR could bind
to the loop sites of pri-miR-7 and reduce the expression of
miR-7 [20], thereby synergizing the transduction of PI3K/
Akt pathway as a positive feedback loop, which ultimately
resulted in enhanced growth and metastatic potential of
human lung cancer cells.
Conclusions
To our knowledge, it is the first time TLR9 signaling was
identified could enhance the expression of HuR in human
lung cancer cells. Importantly, in contrast to previous
findings, we characterized that up-regulation of HuR
was contributed to TLR9 signaling enhanced growth
and metastatic potential of human lung cancer through
altering the expression of miR-7. Our findings indicated
that HuR could act as regulator in regulating TLR9 signal-
ing associated biological effect in human lung cancer cells
through a positive feedback loop, which might be helpful
for the understanding of the potential role of HuR in
tumor biology.
Materials and methods
Reagents and cell line
The following oligonucleotides (ODNs) were used and pur-
chased from Integrated DNATechnologies (Coralville, IO):
CpG ODNs 2216 5′-GGGGGACGATCGTCGGGGG-3′;
control, ODNs1612: 5′-GCTAGAGCTTAGGCT-3′. Hu-
man lung cancer cell line 95D cells, NCI-H727 cells,
BE1 cells and SPCA/I cells were cultured at 37°C under
5% CO2 in completed RPMI 1640 (GIBICO, Grand
land, NY, USA) medium. HuR RNAi and corresponding
control RNAi were purchased from Novus Biologicals
(No.H00001994-R01). Akt inhibitor IV, PI3K inhibitor
(LY294002) and specific MEK (Mitogen-activated protein
kinase) inhibitor (U0126) was purchased from Merck. All
other reagents were purchased from Sigma-Aldrich unless
stated otherwise.
Real-time PCR assay
Total cellular RNA and cDNA were prepared as previously
described [16]. HuR levels were measured by SYBR Green-
based Realtime PCR using Light Cycler (Roche, USA).
Reverse transcriptase reactions and real-time PCR were
performed according to the manufacturer’s protocols. The
sequences were as follows: HuR primers: 5′- CCTGTTCA
GCAGCATTG-3′ and 5′- GGCGAGCATACGACAC-3′.
Cycle threshold (CT) values were compared against a
standard curve to estimate starting amounts of mRNA,
and the relative expression of HuR mRNA was estimated
by normalizing these values against 18S rRNA CT values
were generated using a preoptimized 18S rRNA primerset (Applied Biosystems, FosterCity, CA). The relative
expression of miR-7 was performed according to our
previous description [16].
Plasmid construction and preparation
The gene for the HuR (NM_001419.2) were expanded by
RT-PCR from human mRNA derived from 95D cells using
forward primer (5′- CGGAATTCAATACAATGTCTAA
TGGTTATG-3′) and a reverse primer (5′-GGGGTACCA
TTGGCGCAAAATGAG-3′) and then subcloned into
EcoR I and Kpn I sites of pcDNA3.1 vector (Invitrogen
Corp., San Diego, California, USA) to generate pcDNA3.1-
HuR plasmid (termed as pHuR). Clone identity was verified
using restriction digest analysis and plasmid DNA se-
quencing. Endotoxin-free plasmids were obtained using
Endofree plasmid mega kit (QIAGEN GmbH, Hilden,
Germany). Then, plasmids were transiently transferred
into the 95D cells using Lipofectamine-2000 (Invitrogen)
in different following experiments according to the manu-
facturer’s instruction.
Cell proliferation assays
95D cells transiently transfected with 10 nmol HuR RNAi
or Scramble control using Lipofectamine-2000 (Invitrogen)
were seeded at 3 × 103 cells each well and incubated in the
presence of 10 μg/ml CpG ODNs at 37°C in 5% CO2 in 96
well plates for 72 hrs. Assessment of cell proliferation was
measured in terms of optical absorbance (OD) per well by
a semi-automated tetrazolium-based colorimetric assay
using MTT.
BrdU labeling
95D cells transiently transfected with 10 nmol HuR RNAi
or Scramble control were treated with CpG ODNs as de-
scribed in the previous report [7]. After 48 hrs, final con-
centration of 5 mmol/ml BrdU (5-bromo-2-deoxyuridine;
Sigma) was added. 4 hrs later, 95D cells were collected
and the proliferation was analyzed by FACS.
Invasion assay
The invasive assay was done as described previously
[16]. 95D cells transiently transfected with 10 nmol HuR
RNAi or control RNAi were placed in the upper wells in
the presence of 10 μg/ml CpG ODNs or control ODNs
and the lower wells were filled with fibroblast-conditioned
medium. After incubation for 24 hrs, cells on the lower
surface of the membrane were stained by the H&E method
and counted under a light microscope (×200).
Western blotting
Western blotting was performed on cytosolic cellular
extracts as described previously [16]. The membrane was
washed in 5% skim milk in phosphate buffered saline +
0.03% Tween 20 (PBS-T) for 1 hrs in order to block
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Immunoblotting was performed using a monoclonal
antibody to HuR (Santa Cruz, SC-5261) at a dilution of
1/1000 in a nonfat milk-Tris buffer. The membrane was
then washed and subsequently probed with a correspond-
ing secondary anti-mouse antibody conjugated to horserad-
ish peroxidase (Amersham Life Sciences) at a dilution of
1:5000 and developed with chemiluminescence (Pierce, IL).
The membrane was then exposed to X-ray film (Kodak,
NY) which was subsequently developed.Statistical analyses
Statistical analyses of the data were performed with the
aid of analysis programs in SPSS12.0 software. Statistical
evaluation was performed using one-way analysis of
variance (ANOVA; p < 0.05) using the program PRISM
5.0 (GraphPad Software Inc., San Diego, CA, USA).Additional file
Additional file 1: Figure S1. Overexpression of miR-7 reduced HuR
expression in human lung cancer cells treated with CpG ODNs.Abbreviations
TLRs: Toll like receptors; ODNs: Oligonucleotides; miR-7: microRNA-7;
RNAi: RNA interference; HuR: Human antigen R.
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